KR100856799B1 - Composition for growth-enhancing comprising yeast hydrolysate as an effective ingredient and food using the same - Google Patents

Abstract

A growth promoting composition containing a yeast hydrolysate as an active ingredient is provided to be useful as growth promoting health food and medicine by increasing growth hormone secretion, bone length and weight and realize a growth-promoting function without adverse effect. A growth promoting composition contains a yeast hydrolysate with a molecular weight of 10,000 to 30,000 daltons. The yeast hydrolysate is obtained by adding 0.1 to 3% by weight of a protease selected from the group consisting of Flavourzyme, Protamax, ficin and Neutrase to yeast or self-digestion products of yeast, hydrolyzing at a pH of 6 to 8 and at 45 to 55deg.C and separating from the supernatant. The yeast is Saccharomyces cerevisiae.

Description

Composition for growth-enhancing comprising yeast hydrolysate as an effective ingredient and food using the same}

The present invention relates to a yeast hydrolyzate having a sexual promoting effect and a functional food comprising the same.

Growth refers to the increase in height, and is promoted by nutrition and growth hormone. In particular, the nervous system, including the brain that secretes growth hormone, grows remarkably in childhood, and then grows slowly.

The growth of the long bone determines the height and skeleton, and growth is regulated by special mechanisms. In particular, the growth of the epiphyseal growth plate of the iliac bone is the most important measure for the bone length growth process (Yang, et al., 2003). The growth plate is divided into a proliferation zone for proliferating chondrocytes and a maturation zone and hypertrophic zone for maturation and hypertrophy of chondrocytes. Length growth takes place (Loveridge, 1999).

Recently, as interest in promoting the growth of low-height children, growing interest in growth hormone injections, but this is difficult to take, there is a problem that can cause side effects such as acromegaly, hypothyroidism. Therefore, a method of promoting growth through foods with nutritional supplements such as vitamins and minerals is being sought.

As a natural material that reports growth promoting effects, there are herbal medicines that have been used traditionally. Sung (2005) reported the effects of Nokjung-tang on the growth, dietary efficiency and long-term growth of animals in 5 and 10-week-old male rats. in conjunction in vitro and in There are also reports of parallel investigations in vivo .

On the other hand, yeast ( Saccharomyces cerevisiae ) has been reported to reduce the emotional, physical and behavioral symptoms of premenstrual syndrome by proteolytic enzyme treatment, and has attracted attention as a new material in the functional diet food market, indicating the possibility of appetite suppression.

The present inventors prepare a hydrolyzate using yeast that is used for various purposes in the food field, and prepare a material for functional food development for growth promotion by measuring the effect on the growth of long bone length and the effect of increasing the growth hormone secretion. It was.

It is an object of the present invention to provide a natural material material that is safe and has no growth side effects.

In order to achieve the above object,

According to one aspect of the invention,

Hydrolyzing by adding 0.1 to 3% (w / v) protease to the yeast or autolysate of yeast;

The yeast hydrolyzate obtained by the process comprising the step of separating the substance of molecular weight 10,000-30,000 Daltons from the supernatant of the yeast hydrolyzate and a method for producing the same.

In addition, according to another aspect of the present invention, it is possible to provide a growth promoting functional food comprising the yeast hydrolyzate.

In addition, according to another aspect of the present invention, it is possible to provide a growth accelerator comprising the above-described yeast hydrolyzate.

Hereinafter, the present invention will be described in more detail.

Yeast is recognized as GRAS grade which is harmless to the human body, and more than 50% contains high quality protein, a large amount of minerals and vitamin B group, so it is useful for alcohol and bakery industry. , Vitamins and minerals have been used (Roman et al., Food Biotechnology, 6, 225, 1992).

In addition, yeast extract produced by hydrolysis with yeast autolysis enzyme and other proteolytic enzymes has been used as a raw material for microbial fermentation medium, seasoning, health food, etc. (Bioindustry, 14, 53, 1997).

However, the growth promoting function of the yeast extract or yeast-derived peptides made by hydrolyzing the yeast has not yet been revealed, and the present inventors have measured the effect of the yeast extract or hydrolyzate on the growth of iliac bone and the effect of increasing the growth hormone secretion. It was confirmed for the first time the use for growth promotion by obtaining a significant result.

In the embodiment of the present invention, Saccharomyces cerevisiae was used as the yeast strain, but is not limited thereto, as long as it can be used for food. Such yeast strains include S. carlsbergensis and S. sake .

In addition, the yeast may be a compressed yeast commercially available for edible use, it may be used that cultured in a general culture medium. It is also possible to use yeast in a self-extinguishing state.

When using yeast in the culture state, it is preferable to remove the medium through centrifugation and suspend in distilled water to treat protease.

The protease preferably removes the hydrophobic amino acids of the peptide or produces a peptide without hydrophobic amino acids. As such enzymes, several enzymes known as debittering enzymes can be used to remove the bitter taste. These include, but are not limited to, Flavorzyme, protamax, ficin, neutrase, and the like.

The enzyme may be added at a concentration of 0.1 to 3% (w / v) of the reaction solution. At 0.1% (w / v) or less, the reaction does not occur efficiently, and addition of more than 3% (w / v) of the concentration is uneconomical compared to the reaction yield.

The hydrolysis reaction is preferably carried out at pH 6-8, 45-55 ℃ in terms of hydrolysis reaction efficiency.

After the hydrolysis reaction, the yeast is centrifuged to collect the supernatant to separate peptides / proteins having a molecular weight of 10,000-30,000 Daltons. In the present invention, ultrafiltration was performed for this purpose.

The yeast hydrolyzate prepared as described above was administered to male rats to determine its effect. That is, eight control groups (no administration group), positive control group colostrum 1 g / kg oral administration (P-control), yeast hydrolyzate 0.5 g / kg oral administration (YH-1) and 1.0 g / kg oral administration ( YH-2) was divided into 4 weeks to breed, biochemical analysis, iliac length measurement and growth hormone was measured.

As a result, the experimental group (YH-1 and YH-2) orally administered yeast hydrolyzate and the positive control group (P-control) administered orally with colostrum were compared with the control group. , YH-2) was significantly different from the control group.

The YH-1 and YH-2 groups showed significant differences in the weight gain and the tibial and femur length growth. However, P-control did not show a significant difference from the control.

As a result of measuring the growth plate length of the terminal, the experimental group YH-1 (0.62 mm) and YH-2 (0.56 mm) showed a significant difference from the control group showing 0.17 growth plate size growth.

As shown in FIG. 4, YH-1 (1.77 ng / mL) and YH-2 (2.10 ng / mL) groups were compared with the control group (0.82 ng / mL) even when the amount of growth hormone was measured. There was a significant difference in concentration.

From the above results, it was confirmed that the growth hormone was increased along with the growth of the long bone when the yeast hydrolyzate was ingested, which proves that the yeast hydrolyzate has a growth promoting effect.

Yeast has been used for a long time for food, and since it has already been proven in terms of safety, growth promoting health foods or growth promoting agents using these yeast hydrolysates can be safely consumed.

In view of the above, the present invention may provide a growth promoting health food using the yeast hydrolyzate.

The health food may be prepared by adding other food materials according to the commerciality and consumer preference of the final product.

The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment). In general, in the manufacture of food or beverages the compositions of the invention are added in an amount of up to 15% by weight, preferably up to 10% by weight, based on the total raw material. However, in the case of long-term intake for health and hygiene or for health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. have.

There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages, vitamin complexes, and the like, and includes all of the functional foods in a conventional sense.

The health functional food of the present invention may contain various flavors or natural carbohydrates and the like as additional ingredients, as in general beverages. The preparation example is illustrated below.

The above-mentioned natural carbohydrates are sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as destrin and cyclodextrin, xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.

In addition, the health functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And the carbonizing agent used in the carbonated beverages and the like may contain the flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of from 0.1 to 10 parts by weight per 100 parts by weight of the composition of the present invention.

Of functional drinks Production Example :

522mg of honey

Chioctosanamide 5mg

Nicotinamide 10mg

Riboflavin Sodium Hydrochloride 3mg

Pyridoxine hydrochloride 2mg

Inositol 30mg

Ortic Acid 50mg

Yeast Hydrolyzate 10mg

200ml water

In addition, the present invention can provide a growth accelerator containing the yeast hydrolyzate.

Pharmaceutical products comprising the yeast hydrolyzate of the present invention further comprises suitable carriers, excipients and diluents commonly used in the manufacture of oral dosage forms, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, It can be used in the form of external preparations, suppositories and sterile injectables. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, or the like. Mix and prepare. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The amount of yeast hydrolyzate of the present invention may vary depending on the age, sex, and weight of the patient, but in general, an amount of 0.01 to 1000 mg / kg, preferably 0.1 to 500 mg / kg, may be used once a day. It can be administered in divided doses. In addition, the dosage may be increased or decreased depending on the route of administration, the type and severity of the disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

According to the present invention, a yeast hydrolyzate is provided which is safe, has no side effects and has a growth promoting function. It has the effect of increasing the growth hormone secretion and iliac length and weight, so it is useful as a growth promoting health food or medicine.

Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following examples, and those skilled in the art can make various changes within the spirit and scope of the present invention based on the detailed description and claims of the present invention. It will be appreciated that variations and applications are possible and such variations and applications fall within the scope of the present invention.

Example  1: yeast Hydrolyzate  Produce

8 g of compressed yeast was suspended in 100 ml of distilled water to adjust the pH to 6-8, and then hydrolyzed at 50 ° C. for 48 hours by adding 1.0% of protease (Flavourzyme, Novozymes Korea Limited, 1000 LAPU / g). After centrifugation, the supernatant was collected using ultrafiltration membranes (PM-10 & -30), fractions of 10,000-30,000 in molecular weight, dried, called yeast hydrolysates, and used in subsequent experiments.

Example  2: animal experiment

Laboratory animals

Experimental animals were purchased from Sprague-Dawley male three-week-old rats from central experimental animals (Seoul), and placed in two stainless steel cages, and preliminarily bred for three days with solid feed (Samyang Feed Co., Ltd.) at a temperature of 23 ± 1 ℃ and a humidity of 60%. The control group, the control group, positive control group colostrum 1 g / kg oral administration (P-control), yeast hydrolyzate 0.5 g / kg oral administration (YH-1) and 1.0 g / kg oral administration (YH-2) And experimented for 4 weeks. Eight rats were used per group.

AIN-93 basic diet was to be taken freely. The amount of diet during the experiment was added to the weekly unit to obtain the average daily dietary intake per week. Body weight was measured on a scale at the same time every day, and the feed efficiency ratio (FER) was calculated as the weight gain relative to the measured dietary intake.

Biochemical analysis

On the last day of the 4th week of the experiment, the animals were anesthetized with ether, blood was collected in heparinized tubes, and centrifuged at 3,000 rpm for 15 minutes. Immediately after the blood was collected, the liver, kidneys, and spleens were extracted and weighed. The serum triglyceride, total cholesterol, and HDL cholesterol concentrations were measured using a blood analyzer (Spotchem, KDK Co., Japan), and the concentration of LDL cholesterol was measured by Friedwald et al. (1972). Calculated using (triglyceride / 5).

Iliac length measurement

Before and after the experiment, anesthesia was performed using ether and mammograms were used to measure the tibia, femur and proximal epiphisis. The distance from the plateform was 25 cm during X-ray measurement, and the exposure was taken at 25 kV for 15 seconds. The photographed film was measured for the length of each long bone using a microfilm reader (NCR model 605-0070 837). The length of the tibia was measured in the length of the joint as shown in Figure 1, and the length of the growth plate of the thigh and the tip was also measured.

Growth hormone measurement

Four weeks after the end of the experiment, growth hormone levels were measured using a growth hormone kit (Amersham Pharmacia Biotech, UK) using the ELISA method according to Johansen et al. (1999).

Statistical analysis

The experimental results were statistically analyzed using SPSS (SPSS Inc., USA), and all results were expressed as mean and standard deviation (Mean ± SD). The significance between the experimental groups was verified by Duncan's multiple range test at p <0.05 level after ANOVA test.

Weight change Dietary Intake

Table 4 shows the dietary intake, weight change and dietary efficiency of rats reared for 4 weeks. In the YH-1 and YH-2 groups, the oral administration of yeast hydrolyzate, the weight gain tended to increase significantly compared to the control group (p <0.05), but it was significant between the YH-1 and YH-2 groups. There was no difference. There was a significant difference in dietary efficiency between the control group and the experimental group (P-control, YH-1, YH-2), but there was no significant difference between the experimental groups.

TABLE 1

Organ weight and blood composition

After 4 weeks of breeding, each organ was harvested and weighed (Table 2). The weights of liver, kidney and spleen were not significantly different among the three groups. That is, when orally administered yeast hydrolyzate, specific changes such as enlargement or atrophy of organs could not be observed, and thus the safety of the yeast hydrolyzate of the present invention was confirmed.

As a result of measuring blood glucose, triglyceride, cholesterol, HDL cholesterol and LDL cholesterol content of blood components (Table 3), there was no significant difference in plasma cholesterol, HDL cholesterol and LDL cholesterol content among the three groups.

TABLE 2

TABLE 3

Weight gain and long bone length growth

As a result of measuring weight gain for 4 weeks (FIG. 2), the control group showed 208.3 g, the P-control group 237.2 g, the YH-1 group 230.6 g, and the YH-2 group 233.1 g. There was a significant difference between the control group and the experimental group (P-control, YH-1, YH-2), but there was no significant difference between the experimental group. Body weight gain also showed a significant difference between the experimental group (P-control, YH-1, YH-2) and the control group (p <0.05).

As a result of measuring the length of the iliac bone (Fig. 3), the length of the tibia was increased in the experimental group P-control, YH-1 and YH-2, which were 0.44 mm / day, 0.47 mm / day, and 0.49 mm / day. In contrast, the control group showed an increase of 0.37 mm / day. Femur length growth was also 0.43 mm / day, 0.52 mm / day and 0.55 mm / day in the experimental groups P-control, YH-1 and YH-2, respectively, while the control group grew 0.42 mm / day. Showed. In the experimental group, YH-1 and YH-2 showed significant differences in the growth of the tibia and femur compared to the control group ( p < 0.05). However, the experimental group P-control did not show a significant difference from the control group.

As a result of measuring the growth plate length of the terminal (Fig. 3), the experimental group YH-1 (0.62 mm) and YH-2 (0.56 mm) showed a significant difference from the control group showing 0.17 growth plate size growth.

Growth hormone

As a result of measuring the amount of growth hormone after 4 weeks (FIG. 4), the YH-1 (1.77 ng / mL) and YH-2 (2.10 ng / mL) groups were compared with the control group (0.82 ng / mL). There was a significant difference in concentration. YH-1 and 2 groups also showed significant differences in growth hormone levels.

1 is a radiograph showing the morphometric parameters of the femur and tibia,

T.L: total tibia length, P.E.L .: distal growth plate length, F.L: femur length

2 is a graph showing the effect of the enzymatic hydrolyzate of the present invention on weight change,

3 is a graph showing the effect of the enzymatic hydrolyzate of the present invention on the femur, tibia and terminal growth plate length,

Figure 4 is a graph showing the effect of the enzyme hydrolyzate of the present invention on growth hormone levels,

5 is a graph showing the molecular weight distribution of the fraction obtained by the ultrafiltration treatment of the yeast hydrolyzate of the present invention, showing the molecular weight distribution of the yeast hydrolyzate having a molecular weight of 5000 or less, 5000-10000 and 10000-30000.

Claims (8)

0.1 to 3% (w / v) of protease selected from the group consisting of Flavorzyme, Protamax, Picin and Neutrase in yeast or yeast autolysate ) A composition having a growth promoting effect containing yeast hydrolyzate having a molecular weight of 10,000-30,000 Daltons, obtained from the supernatant as an active ingredient. 0.1 to 3% (w / v) of protease selected from the group consisting of Flavorzyme, Protamax, Picin and Neutrase in yeast or yeast autolysate Hydrolysis by addition); And A method for producing a composition having a growth promoting effect according to claim 1, which is obtained by a process comprising separating a substance having a molecular weight of 10,000-30,000 Daltons from the supernatant of the yeast hydrolyzate. The method of claim 2, wherein the hydrolysis reaction is performed at pH 6-8 and 45-55 ° C. 4. Growth promoting food comprising the composition of claim 1. A growth promoter comprising the composition of claim 1. delete delete delete

Images